These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33067264)

  • 41. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
    Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
    Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells.
    Okamoto K; Tajima H; Ohta T; Nakanuma S; Hayashi H; Nakagawara H; Onishi I; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Tani T; Fujimura T; Kayahara M; Harada S; Wakayama T; Iseki S
    Int J Oncol; 2010 Nov; 37(5):1251-9. PubMed ID: 20878072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
    Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
    Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.
    Ohira S; Sasaki M; Harada K; Sato Y; Zen Y; Isse K; Kozaka K; Ishikawa A; Oda K; Nimura Y; Nakanuma Y
    Am J Pathol; 2006 Apr; 168(4):1155-68. PubMed ID: 16565491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PARP-1 selectively impairs
    Keggenhoff FL; Castven D; Becker D; Stojkovic S; Castven J; Zimpel C; Straub BK; Gerber T; Langer H; Hähnel P; Kindler T; Fahrer J; O'Rourke CJ; Ehmer U; Saborowski A; Ma L; Wang XW; Gaiser T; Matter MS; Sina C; Derer S; Lee JS; Roessler S; Kaina B; Andersen JB; Galle PR; Marquardt JU
    Gut; 2024 Sep; 73(10):1712-1724. PubMed ID: 38857989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
    Namikawa M; Fukuda A; Mizukoshi K; Iwane K; Kawai M; Yamakawa G; Omatsu M; Sono M; Masuda T; Araki O; Nagao M; Yoshikawa T; Ogawa S; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Tsuruyama T; Taura K; Hatano E; Seno H
    J Pathol; 2023 Aug; 260(4):478-492. PubMed ID: 37310065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.
    El Khatib M; Bozko P; Palagani V; Malek NP; Wilkens L; Plentz RR
    PLoS One; 2013; 8(10):e77433. PubMed ID: 24204826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
    Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
    Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.
    Shimizu T; Yokomuro S; Mizuguchi Y; Kawahigashi Y; Arima Y; Taniai N; Mamada Y; Yoshida H; Akimaru K; Tajiri T
    World J Gastroenterol; 2006 Oct; 12(39):6316-24. PubMed ID: 17072955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma.
    Zhou Q; Wang Y; Peng B; Liang L; Li J
    BMC Cancer; 2013 May; 13():244. PubMed ID: 23688168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
    Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
    Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease and the cholangiocarcinomatous component of hepatocellular cholangiocarcinoma share common phenotypes and cholangiocarcinogenesis.
    Xu J; Sasaki M; Harada K; Sato Y; Ikeda H; Kim JH; Yu E; Nakanuma Y
    Histopathology; 2011 Dec; 59(6):1090-9. PubMed ID: 22175889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
    Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. USP10 promotes intrahepatic cholangiocarcinoma cell survival and stemness via SNAI1 deubiquitination.
    Zhu W; Ye B; Yang S; Li Y
    J Mol Histol; 2023 Dec; 54(6):703-714. PubMed ID: 37755617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
    Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
    Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma.
    Li H; Wu Z; Zhong R; Zhang Q; Chen Q; Shen Y
    Med Oncol; 2022 Oct; 39(12):250. PubMed ID: 36209344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
    Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
    Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.